Jéssica Estefania Dávila Hidalgo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jéssica Estefania Dávila Hidalgo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- David A. Stevens
Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
2 shared publications - Mariana Rodrigues Trápaga
Programa de Pós-Graduação em Ciências da Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-190, RS, Brazil
2 shared publications - Melissa Orzechowski Xavier
Programa de Pós-Graduação em Ciências da Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-190, RS, Brazil
2 shared publications - Monica Campos dos Santos
Programa de Pós-Graduação em Ciências das Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-200, RS, Brazil
2 shared publications - Vanice Rodrigues Poester
Programa de Pós-Graduação em Ciências da Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-190, RS, Brazil
2 shared publications - Abdullah M. S. Al Hatmi
Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman
1 shared publication
Latest Publications
- Open Access
- 14 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 1018
In Vitro Activity of Organoselenium Compounds Against Trichophyton spp.
Background/Objectives: Dermatophytosis is among the most prevalent fungal infections worldwide, and the emergence of antifungal resistance highlights the need for novel the-rapeutic strategies. Organoselenium compounds have demonstrated promising antifungal activity against several pathogenic fungi, although their activity against dermatophytes remains poorly explored. Here we investigate the in vitro antifungal activity of four organoselenium compounds, ebselen, diphenyl diselenide [(PhSe)2], p-methoxy-diphenyl diselenide (BMD), and bis-(3-trifluoromethyl phenyl) diselenide (CF3). Methods: Eighteen clinical isolates belonging to the T. mentagrophytes (n = 10) and T. rubrum (n = 8) species complexes were studied and potential synergism with fluconazole (FCZ) also explored. Antifungal susceptibility testing and drug interaction were performed according to Clinical and Laboratory Standards Institute broth microdilution protocols and checkerboard assay, respectively. Results: Ebselen, (PhSe)2, and BMD inhibited all Trichophyton spp. isolates with a geometric mean (GM) of minimum inhibitory concentration (MIC) less than or equal to 6 µg/mL. CF3 inhibited 78% (14/18) of the isolates and had higher MICs (GM ≥ 43.5 µg/mL). Combination assays revealed synergistic interactions between FCZ and the organoselenium compounds, ranging from 45% to 89%, without antagonistic interactions. Moreover, FCZ activity was enhanced in 57–86% of resistant isolates, with BMD showing the most favorable profile in combination with FCZ. Conclusions: These findings demonstrate the promising antifungal potential of organoselenium compounds against the major dermatophytes associated with human infection and support further investigation of these compounds, particularly ebselen, (PhSe)2, and BMD, as novel antifungal agents, either alone or in combination with conventional antifungal drugs.
- 14 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 1018
Open AccessIn Vitro Activity of Organoselenium Compounds Against Trichophyton spp.
Background/Objectives: Dermatophytosis is among the most prevalent fungal infections worldwide, and the emergence of antifungal resistance highlights the need for novel the-rapeutic strategies. Organoselenium compounds have demonstrated promising antifungal activity against several pathogenic fungi, although their activity against dermatophytes remains poorly explored. Here we investigate the in vitro antifungal activity of four organoselenium compounds, ebselen, diphenyl diselenide [(PhSe)2], p-methoxy-diphenyl diselenide (BMD), and bis-(3-trifluoromethyl phenyl) diselenide (CF3). Methods: Eighteen clinical isolates belonging to the T. mentagrophytes (n = 10) and T. rubrum (n = 8) species complexes were studied and potential synergism with fluconazole (FCZ) also explored. Antifungal susceptibility testing and drug interaction were performed according to Clinical and Laboratory Standards Institute broth microdilution protocols and checkerboard assay, respectively. Results: Ebselen, (PhSe)2, and BMD inhibited all Trichophyton spp. isolates with a geometric mean (GM) of minimum inhibitory concentration (MIC) less than or equal to 6 µg/mL. CF3 inhibited 78% (14/18) of the isolates and had higher MICs (GM ≥ 43.5 µg/mL). Combination assays revealed synergistic interactions between FCZ and the organoselenium compounds, ranging from 45% to 89%, without antagonistic interactions. Moreover, FCZ activity was enhanced in 57–86% of resistant isolates, with BMD showing the most favorable profile in combination with FCZ. Conclusions: These findings demonstrate the promising antifungal potential of organoselenium compounds against the major dermatophytes associated with human infection and support further investigation of these compounds, particularly ebselen, (PhSe)2, and BMD, as novel antifungal agents, either alone or in combination with conventional antifungal drugs.
- Open Access
- 2 March 2026
- Published by Microbiology Society in Microbiology
- Vol. 172 (3) , 001663
Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens
Background. Natural host defence molecules, part of innate immunity and the first line of defence, are evolutionarily conserved. Some pharmaceutical properties undesirable for clinical use led to the rational design of synthetic molecules with constructed peptide arrangements, giving a novel therapeutic avenue. A prior publication showed synthetic peptide RP557 inhibition and killing of fluconazole-sensitive and resistant Candida species isolates, biofilm inhibition, no resistance induction, direct membrane action, negligible mammalian cell toxicity and topical efficacy in a rodent vaginal candidiasis model. These findings highlight the relevance of investigating RP557 activity against other fungal pathogens. Objective. We evaluated the antifungal spectrum of the RP557 against World Health Organization-listed priority fungal pathogens, including endemic and skin fungal pathogens, both alone and in combination with commercial antifungal drugs. Methods. The antifungal spectrum was evaluated by broth dilution vs. clinical isolates, and we present 76 MICs (mcg ml −1 ) performed according to M27 or M38 CLSI documents, 35 checkerboard interactions with antifungals and 10 minimum fungicidal determinations. Results. Overall impression is robust activity vs. chromoblastomycosis and mycetoma species, Cryptococcus neoformans and Trichophyton spp.; broad MIC ranges within most species, least activity vs. Mucorales and Aspergillus spp.; and some promising drug interactions vs. Sporothrix spp. and Candida auris . Conclusion. Additional efficacy data in vivo is needed. Topical therapy could give local concentrations exceeding MICs, and burn or trauma prophylaxis or treatments are attractive potential targets owing to RP557 panmicrobial properties.
- 2 March 2026
- Published by Microbiology Society in Microbiology
- Vol. 172 (3) , 001663
Open AccessAntifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens
Background. Natural host defence molecules, part of innate immunity and the first line of defence, are evolutionarily conserved. Some pharmaceutical properties undesirable for clinical use led to the rational design of synthetic molecules with constructed peptide arrangements, giving a novel therapeutic avenue. A prior publication showed synthetic peptide RP557 inhibition and killing of fluconazole-sensitive and resistant Candida species isolates, biofilm inhibition, no resistance induction, direct membrane action, negligible mammalian cell toxicity and topical efficacy in a rodent vaginal candidiasis model. These findings highlight the relevance of investigating RP557 activity against other fungal pathogens. Objective. We evaluated the antifungal spectrum of the RP557 against World Health Organization-listed priority fungal pathogens, including endemic and skin fungal pathogens, both alone and in combination with commercial antifungal drugs. Methods. The antifungal spectrum was evaluated by broth dilution vs. clinical isolates, and we present 76 MICs (mcg ml −1 ) performed according to M27 or M38 CLSI documents, 35 checkerboard interactions with antifungals and 10 minimum fungicidal determinations. Results. Overall impression is robust activity vs. chromoblastomycosis and mycetoma species, Cryptococcus neoformans and Trichophyton spp.; broad MIC ranges within most species, least activity vs. Mucorales and Aspergillus spp.; and some promising drug interactions vs. Sporothrix spp. and Candida auris . Conclusion. Additional efficacy data in vivo is needed. Topical therapy could give local concentrations exceeding MICs, and burn or trauma prophylaxis or treatments are attractive potential targets owing to RP557 panmicrobial properties.